Figure 7.

The TAT–glucocorticoid-induced leucine zipper (GILZ) fusion protein reverses the symptoms of dinitrobenzene sulfonic acid (DNBS)-induced colitis. (A) Loss of body weight in wild-type (WT) and gilz B cKO mice treated intrarectally with vehicle (Sham) or DNBS, with and without administration of TAT–GILZ fusion protein (daily i.p. administration of 0.5 mg/kg, starting from day 0). (B) Daily measurement of total disease score in WT and gilz B cKO mice during DNBS-induced colitis, treated with or without TAT–GILZ fusion protein. (C) Colon weight/length ratio of WT and gilz B cKO mice intrarectally administered with vehicle (Sham) or DNBS, treated with and without TAT–GILZ fusion protein. Data are from two independent experiments (n = 6, 7). N.S., not significant, statistical analysis was performed using the unpaired Student’s t-test (*p < 0.05, **p < 0.005).